Grants and Contributions:
Title:
Development of Multiple Rapid Antigen Tests for Infectious Diseases
Agreement Number:
993817
Agreement Value:
$3,000,000.00
Agreement Date:
Jun 1, 2022 - Mar 31, 2025
Description:
This project will support the firm’s development of 2 separate platforms for in vitro diagnostic test kits for infectious diseases that enable detection of disease antigens at industry leading speed. The project will also support the development of a number of new Point of Care (POC) or Self Test (SF) built upon the two new platforms, as well as the development of new processes for bioproduction and for automating the manufacture of the test kits
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Richmond, British Columbia, CA V6V 2A2
Reference Number:
172-2022-2023-Q2-993817
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
869859116
Recipient Type:
For-profit organization
Recipient's Legal Name:
BioLytical Laboratories Inc.
Federal Riding Name:
Steveston--Richmond East
Federal Riding Number:
59031
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
334512